What is the 13F Pro Quality Score for BCPC?

13F Pro ranks BALCHEM CORP (BCPC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BCPC's current score at https://13fpro.ai/company/BCPC (free sign-up required for the full ranking).

Where does 13F Pro source BCPC data?

All BALCHEM CORP fundamentals and ownership data come directly from SEC EDGAR. BALCHEM CORP files with the SEC under CIK 9326. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BCPC in?

BALCHEM CORP (BCPC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives BCPC's revenue?

Per BALCHEM CORP's latest 10-Q filed with the SEC on 2026-07-31, the biggest revenue drivers are: Human Nutrition & Health ($176.9M, +10.0% YoY); Animal Nutrition & Health ($64.5M, +15.0% YoY); Specialty Products ($40.5M, +8.9% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/BCPC.

How often is BCPC research updated on 13F Pro?

BCPC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BALCHEM CORP(BCPC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 9326 BCPC stock profile & AI dashboard →

13F Pro Quality Score

64.5/100

Rank #539 of 2,962 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

53.2/100

Profitability

73.9/100

Balance Sheet

84.9/100

Earnings Quality

70.1/100

Free Cash Flow

73.4/100

Institutional Flow

57.9/100

Revenue Scale

51.3/100

Dilution Risk

42.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BCPC Scores 65/100

exact factor attribution · 2026-09-11

BCPC's composite is driven by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+3.6 pts

74th pct

Free cash flow

+3.5 pts

73th pct

Capital efficiency

+3.5 pts

85th pct

Earnings quality

+2.0 pts

70th pct

Earnings growth

+1.1 pts

71th pct

Revenue growth

+0.6 pts

53th pct

Institutional flow

+0.4 pts

58th pct

Scale

+0.2 pts

51th pct

Shareholder dilution

-0.4 pts

43th pct

Latest change (2026-08-02): 66 → 65 · ↓ Earnings growth 67→56

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

BCPC Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for BALCHEM CORP (BCPC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BCPC at 64.5/100 on a 32-signal composite quality model, placing it at rank #539 of 2,962 stocks — the top 25% of the AI-ranked universe. BCPC scores in the top quartile across balance sheet strength (84.9). Shareholder dilution risk is elevated at 42.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BALCHEM CORP reports quarterly revenue of $284.0M, net income of $44.6M, an operating margin of 20.8%. Top institutional holders of BCPC by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BCPC trades on the Nasdaq exchange and files with the SEC under CIK 9326. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCPC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BALCHEM CORP directly from SEC EDGAR. BALCHEM CORP's 13F Pro composite quality score has ranged between 53 and 68 since 2021, currently 64.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about BALCHEM CORP

Quirks, history, and lore behind BCPC — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty chemicals company · listed on Nasdaq · serves the human nutrition, animal health, and industrial markets · headquartered in New Jersey.
2
The Numbers
Annual revenue in the range of $800 million to $900 million — not a giant, but a small-cap compounder with consistently strong margins that Wall Street quietly loves.
3
The History
Founded in the 1960s, it built its early business around a deceptively simple technology: encapsulating sensitive ingredients so they survive processing and deliver where they're needed.
4
The Secret
Its core trick is microencapsulation — coating nutrients, minerals, or chemicals in a protective shell so they don't react, degrade, or smell bad before reaching their target.
5
The Lore
It is one of the world's leading producers of choline — a nutrient most people have never heard of but that goes into baby formula, animal feed, and dietary supplements globally.
6
The Giveaway
Ticker BCPC, this Balchem-sounding outfit has quietly encapsulated its way to decades of steady growth — one tiny coated particle at a time.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving BCPC's Business? Latest 10-Q Breakdown

✓ 27/27 datapoints verified

AI-extracted from BALCHEM CORP's 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Balchem grew Q2 net sales 11.2% YoY to $284.0M, with earnings from operations up 15.1% to $59.2M as all three segments posted higher volume, mix, and pricing.

Biggest Revenue Drivers

Human Nutrition & Health$176.9M+10.0% YoY

Driven by higher sales in both the nutrients business and the food ingredients and solutions businesses

Animal Nutrition & Health$64.5M+15.0% YoY

Driven by higher sales in both the monogastric and ruminant species markets

Biggest Revenue Drivers

Total revenue: $284.0M+11.2% YoY

Human Nutrition & Health$176.9M+10.0% YoY

Driven by higher sales in both the nutrients business and the food ingredients and solutions businesses

Animal Nutrition & Health$64.5M+15.0% YoY

Driven by higher sales in both the monogastric and ruminant species markets

Specialty Products$40.5M+8.9% YoY

Due to higher sales in both the performance gases and plant nutrition businesses

Other and Unallocated$2.1M+44.4% YoY

Largest Expense Items

Cost of sales$180.3M+11.1% YoY

Rose with sales growth, partially offset by manufacturing efficiencies

Selling expenses$21.1M+9.5% YoY

General and administrative expenses$18.8M+4.0% YoY

Operating expense growth overall was primarily due to higher compensation-related costs of $2,942K

Research and development expenses$4.5M+5.4% YoY

Margins: Gross margin rose to 36.5% of net sales from 36.4%, on sales growth and manufacturing efficiencies partially offset by higher manufacturing input costs; operating margin improved to 20.9% from 20.1%.

Watch Items from the Filing

Company entered Amendment No. 1 to its credit agreement on July 24, 2026, raising the revolver from $550M to $650M and extending maturity to 2031, used to repay the $152M outstanding balance.
U.S. Supreme Court invalidated certain IEEPA tariffs in February 2026, followed by new tariffs under other authorities; Balchem says it cannot yet estimate the total financial impact.
Company continues remediation and investigation activity at its Verona, Missouri Superfund site (dioxin contamination) and settled EPA/DOJ Clean Air Act allegations in January 2025 for a $300K penalty plus $350K community spending.
Effective tax rate rose to 22.8% from 21.9% YoY, primarily due to lower tax benefits from stock-based compensation.
Company repatriated $23,460K from its Belgium subsidiary during Q2 2026 to pay down U.S. debt, out of $53,925K total cash held by foreign subsidiaries.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$284.0M

Net Income

Q2 2026

$44.6M

Operating Margin

Q2 2026

20.8%

ROIC

Q2 2026

18.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+8.8% YoY

$1.04BFY 2025

FY22 $942.4MFY23 $922.4MFY24 $953.7MFY25 $1.04B

Net Income

+20.5% YoY

$154.8MFY 2025

FY22 $105.4MFY23 $108.5MFY24 $128.5MFY25 $154.8M

Operating Income

+14.4% YoY

$209.3MFY 2025

FY22 $145.2MFY23 $159.2MFY24 $182.9MFY25 $209.3M

EPS (Diluted)

+20.9% YoY

$4.75FY 2025

FY22 $3.25FY23 $3.35FY24 $3.93FY25 $4.75

Total Assets

+7.0% YoY

$1.69BFY 2025

FY22 $1.62BFY23 $1.60BFY24 $1.58BFY25 $1.69B

Op. Cash Flow

+19.0% YoY

$216.6MFY 2025

FY22 $138.5MFY23 $183.8MFY24 $182.0MFY25 $216.6M

Free Cash Flow

—FY 2025

FY22 $89.5MFY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.04B +8.8%	$953.7M +3.4%	$922.4M -2.1%	$942.4M +17.9%	$799.0M +13.6%	$703.6M
Net Income	$154.8M +20.5%	$128.5M +18.4%	$108.5M +3.0%	$105.4M +9.6%	$96.1M +13.6%	$84.6M
Operating Income	$209.3M +14.4%	$182.9M +14.9%	$159.2M +9.6%	$145.2M +13.9%	$127.5M +14.7%	$111.1M
EPS (Diluted)	$4.75 +20.9%	$3.93 +17.3%	$3.35 +3.1%	$3.25 +10.5%	$2.94 +13.1%	$2.60
Total Assets	$1.69B +7.0%	$1.58B -1.4%	$1.60B -1.7%	$1.62B +35.5%	$1.20B +2.9%	$1.17B
Operating Cash Flow	$216.6M +19.0%	$182.0M -1.0%	$183.8M +32.6%	$138.5M -13.7%	$160.5M +6.7%	$150.5M
Free Cash Flow	—	—	—	$89.5M -28.1%	$124.4M +5.0%	$118.4M

Get alerted when BCPC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BALCHEM CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BCPC

BlackRock, Inc.
$838.7M4,964,479 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$375.3M2,221,267 sh
VANGUARD CAPITAL MANAGEMENT LLC
$244.2M1,445,369 sh
STATE STREET CORP
$216.5M1,281,552 sh
GEODE CAPITAL MANAGEMENT, LLC
$189.6M1,122,146 sh
Conestoga Capital Advisors, LLC
$183.8M1,087,871 sh
WASATCH ADVISORS LP
$177.5M1,050,780 sh
MORGAN STANLEY
$141.0M834,445 sh
GENEVA CAPITAL MANAGEMENT LLC
$115.4M683,102 sh
FIRST TRUST ADVISORS LP
$104.3M617,233 sh

Fund	Value	Shares
BlackRock, Inc.	$838.7M	4,964,479
VANGUARD PORTFOLIO MANAGEMENT LLC	$375.3M	2,221,267
VANGUARD CAPITAL MANAGEMENT LLC	$244.2M	1,445,369
STATE STREET CORP	$216.5M	1,281,552
GEODE CAPITAL MANAGEMENT, LLC	$189.6M	1,122,146
Conestoga Capital Advisors, LLC	$183.8M	1,087,871
WASATCH ADVISORS LP	$177.5M	1,050,780
MORGAN STANLEY	$141.0M	834,445
GENEVA CAPITAL MANAGEMENT LLC	$115.4M	683,102
FIRST TRUST ADVISORS LP	$104.3M	617,233

Companies Similar to BCPC

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

MEDP

Medpace Holdings, Inc.

AI score

Similar quality profile · 14 shared holders

WASATCH ADVISORS LP Stephens Investment Management Group LLC Clearbridge Investments, LLC

MMSI

MERIT MEDICAL SYSTEMS INC

AI score

Similar quality profile · 18 shared holders

Conestoga Capital Advisors, LLC CONGRESS ASSET MANAGEMENT CO /MA WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC

IDXX

IDEXX LABORATORIES INC /DE

AI score

Similar quality profile · 12 shared holders

CONGRESS ASSET MANAGEMENT CO /MA WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Stephens Investment Management Group LLC

GMED

GLOBUS MEDICAL INC

AI score

Similar quality profile · 13 shared holders

GENEVA CAPITAL MANAGEMENT LLC WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Stephens Investment Management Group LLC

RMD

RESMED INC

AI score

Similar quality profile · 12 shared holders

Stephens Investment Management Group LLC VOLORIDGE INVESTMENT MANAGEMENT, LLC Vest Financial, LLC

MSA

MSA Safety Inc

AI score

Similar quality profile · 13 shared holders

Conestoga Capital Advisors, LLC EULAV Asset Management Vest Financial, LLC

EHC

Encompass Health Corp

AI score

Similar quality profile · 13 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC CONGRESS ASSET MANAGEMENT CO /MA SEGALL BRYANT & HAMILL, LLC

STE

STERIS plc

AI score

Similar quality profile · 8 shared holders

Clearbridge Investments, LLC CONGRESS ASSET MANAGEMENT CO /MA Boston Trust Walden Corp

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BCPC on your watchlist

Track score changes the day BALCHEM CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BCPC a good stock to buy?

13F Pro's AI-powered analysis of BALCHEM CORP (BCPC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BCPC are available on the BCPC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BCPC is classified as a mid company.

Which hedge funds own BCPC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BCPC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BALCHEM CORP's investment landscape.